Medication assisted treatment for substance use disorder
Pro Research Analysisby 
Searched over 200M research papers
Overview of Medication-Assisted Treatment (MAT) for Substance Use Disorder
Medication-assisted treatment (MAT) is a key approach for managing substance use disorders (SUDs), especially opioid use disorder (OUD). MAT combines FDA-approved medications with counseling and behavioral therapies to provide a comprehensive treatment plan. The most commonly used medications for OUD are methadone, buprenorphine, and naltrexone, each with proven effectiveness in reducing opioid use and improving treatment retention 1246.
Efficacy of MAT Medications for Opioid Use Disorder
Research consistently shows that MAT significantly increases the chances of opioid abstinence compared to psychosocial treatment alone or placebo. Methadone maintenance is considered the gold standard, but buprenorphine (alone or combined with naloxone) also demonstrates strong efficacy and safety, including for special populations such as youth and pregnant women. Naltrexone, especially in its extended-release form, is less likely to be misused but has weaker evidence for effectiveness due to adherence challenges 1246.
MAT in Correctional Settings
Studies in prison and jail settings show that providing MAT, particularly methadone, during incarceration increases engagement in community treatment after release and reduces illicit opioid use and injection drug use. Buprenorphine and naltrexone are also effective, but more research is needed to compare their outcomes directly. However, MAT does not appear to significantly reduce recidivism rates .
Functional Outcomes and Limitations
MAT patients generally perform better on some functional outcomes, such as employment and reduced criminal activity, compared to those who do not receive MAT. However, they may perform worse on certain cognitive measures compared to healthy controls. The quality of evidence for these findings is low, and more research is needed to clarify the impact of MAT on various aspects of functioning .
Barriers to MAT Implementation
Despite strong evidence for MAT’s effectiveness, its adoption remains limited. Key barriers include regulatory restrictions, lack of medical staff, funding issues, and limited access to providers with MAT expertise. Stigma and confusion around the term "medication-assisted treatment" may also contribute to underutilization, as it can imply that medication is secondary to other treatments rather than a primary, evidence-based intervention 3578.
Expanding Access and Reducing Stigma
Primary care providers, especially in rural areas, are well-positioned to deliver MAT, but more support and training are needed. The COVID-19 pandemic has prompted changes in MAT delivery, such as increased use of telehealth, which may improve access. Experts recommend using clear, person-first language and referring to MAT simply as "medication" for SUD, similar to how medications are discussed for other chronic conditions, to help reduce stigma and improve care 258.
MAT for Other Substance Use Disorders
Beyond opioids, MAT is also used for alcohol use disorder (with medications like disulfiram, acamprosate, and naltrexone) and tobacco use disorder (with nicotine replacement therapies, bupropion, and varenicline). There is ongoing research into medications for other substances, but fewer FDA-approved options exist .
Conclusion
Medication-assisted treatment is a highly effective, evidence-based approach for opioid use disorder and other substance use disorders. While MAT improves treatment retention and reduces opioid use, significant barriers to access and persistent stigma remain. Addressing these challenges through policy changes, improved medical infrastructure, and better language can help expand the reach and impact of MAT for those in need 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic